Top ▲

CoV RNA-dependent RNA polymerase

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 3139

Nomenclature: CoV RNA-dependent RNA polymerase

Family: Coronavirus (CoV) proteins

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Gene and Protein Information Comments
SARS-CoV RdRp is a 932 amino acid protein that is amino acids 4370-5301 of the polyprotein encoded by Orf1b.
SARS-CoV-2 RdRp is a 932 amino acid protein that is amino acids 4393-5324 of the polyprotein encoded by Orf1b.
Previous and Unofficial Names Click here for help
non-structural protein 12 | nsp12
Database Links Click here for help
ChEMBL Target

Download all structure-activity data for this target as a CSV file go icon to follow link

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
remdesivir Small molecule or natural product Approved drug SARS-CoV-2 Inhibition - - 1
remdesivir Small molecule or natural product Approved drug Click here for species-specific activity table SARS-CoV Inhibition - - 1
View species-specific inhibitor tables
General Comments
Coronavirus RdRp is a highly investigated molecular target for antiviral drug development [2,5-6], and is the target of the much publicised drug remdesivir. Although RdRp (nsp12) is strictly a component of the SARS-CoV-2 replicase polyprotein we have included it as a separate entity to allow us to more sensibly curate pharmacological information (particularly regarding inhibitor development) that is specific for this enzyme. RdRp functions as a component of a genome replication protein complex that also contains nsp7 and nsp8 [3-4]. RdRp-mediated replication can be primer-dependent, but RdRp is also capable of de novo (primer-independent) RNA synthesis [3]. Because of the conserved structure of the key drug-binding pockets between SARS-CoV-2, SARS-CoV, and MERS-CoV RdRps, redeploying known SARS-CoV and MERS-CoV inhibitors for SARS-CoV-2 is an obvious strategy to combat SARS-CoV-2. To enhance therapeutic efficacy a sensible strategy would be to develop a multi-targeted combination of RdRp inhibitors with approved or clinical-stage drug candidates against other viral and/or host proteins.


Show »

1. Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Götte M. (2020) Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem, 295 (20): 6785-6797. [PMID:32284326]

2. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL et al.. (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 583 (7816): 459-468. [PMID:32353859]

3. Imbert I, Guillemot JC, Bourhis JM, Bussetta C, Coutard B, Egloff MP, Ferron F, Gorbalenya AE, Canard B. (2006) A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus. EMBO J, 25 (20): 4933-42. [PMID:17024178]

4. Kirchdoerfer RN, Ward AB. (2019) Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun, 10 (1): 2342. [PMID:31138817]

5. Shahid M, Shahzad-Ul-Hussan S. (2020) Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2. J Struct Biol, 213 (1): 107690 [Epub ahead of print]. [PMID:33383190]

6. Zhu W, Chen CZ, Gorshkov K, Xu M, Lo DC, Zheng W. (2020) RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. SLAS Discov, 25 (10): 1141-1151. [PMID:32660307]

How to cite this page